GSK Out-Licenses Liver Disease Drug Linerixibat to Alfasigma for Up to $690M

summarizeSummary

GSK has entered a licensing agreement with Alfasigma for the worldwide rights to linerixibat, an investigational drug for cholestatic pruritus in PBC, receiving an upfront payment of $300 million and potential milestones up to $390 million.

check_boxKey Events

• Licensing Agreement for Linerixibat

  GSK granted Alfasigma worldwide exclusive rights to develop, manufacture, and commercialize linerixibat, an investigational drug for cholestatic pruritus in primary biliary cholangitis (PBC).

• Significant Financial Terms

  GSK will receive an upfront payment of $300 million, an additional $100 million upon US FDA approval, $20 million upon EU and UK approval, and up to $270 million in sales-based milestone payments, plus tiered double-digit royalties on net sales worldwide.

• Strategic Portfolio Focus

  This agreement allows GSK to sharpen its focus on its next wave of liver disease innovation, including potential treatments for chronic hepatitis B, MASH, and ALD.

• Advanced Regulatory Status

  Linerixibat has Orphan Drug Designation in the US, EU, and Japan, and priority review in China, with marketing applications currently under regulatory review in multiple regions based on positive Phase III trial data.

auto_awesomeAnalysis

This agreement allows GSK to divest a late-stage asset with positive Phase III data and regulatory applications under review, while securing significant non-dilutive capital. The deal, valued at up to $690 million including milestones, enables GSK to sharpen its focus on other promising liver disease innovations in its pipeline, such as treatments for chronic hepatitis B, MASH, and ALD. For Alfasigma, it strengthens their specialty care and rare disease portfolio, particularly in liver diseases.